前列腺SABR同步局灶加量至大体肿瘤的耐受性评估:两项前瞻性试验的毒性与生活质量比较
结果显示同步DIL加量组与未加量组在急性≥2级胃肠/泌尿毒性、24个月内累积最重晚期毒性及生活质量评分上均无显著差异,提示该方案可行。
要点
- 前列腺及盆腔SABR同步DIL加量至50 Gy/5次可行。
- 急性≥2级胃肠或泌尿毒性两组无显著差异。
- 24个月内晚期毒性及生活质量两组无显著差异。
核心结论
- 前列腺及盆腔SABR同步DIL加量是可行的,急性≥2级毒性、晚期毒性及生活质量与未加量队列似乎相当。
研究设计与样本
- 第一项试验高危患者前列腺40 Gy、盆腔25 Gy;第二项试验中高危患者前列腺35 Gy、盆腔25 Gy、DIL加量至50 Gy。
主要发现
- 局灶加量队列DIL D90%中位值为48.3 Gy。
- 两组急性≥2级胃肠或泌尿毒性无显著差异。
- 两组24个月内累积最重晚期胃肠或泌尿毒性无显著差异。
- 两组生活质量各领域评分及最小临床重要变化无显著差异。
临床怎么用
- 可考虑对MRI可见的DIL行同步SABR加量,短期毒性与生活质量未见明显增加。
局限性
- 需进一步随访评估长期结局。
- 需随机对照数据确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Dose-escalated stereotactic ablative radiotherapy (SABR) to the whole prostate may be associated with better outcomes but has a risk of increased toxicity. An alternative approach is to focally boost the dominant intraprostatic lesion (DIL) seen on magnetic resonance imaging. We report the toxicity and quality-of-life (QOL) outcomes of 2 phase 2 trials of prostate and pelvic SABR, with or without a simultaneous DIL boost. METHODS AND MATERIALS: The first trial treated patients with high-risk prostate cancer to a dose of 40 Gy to the prostate and 25 Gy to the pelvis in 5 fractions. The second trial treated patients with intermediate-risk and high-risk prostate cancer to a dose of 35 Gy to the prostate, 25 Gy to the pelvis, and a DIL boost up to 50 Gy in 5 fractions. Acute toxicities, late toxicities, and QOL were assessed. RESULTS: Thirty patients were enrolled in each trial. In the focal boost cohort, the median DIL D90% was 48.3 Gy. There was no significant difference in acute grade ≥2 gastrointestinal or genitourinary toxicity between the 2 trials or in cumulative worst late gastrointestinal or genitourinary toxicity up to 24 months. There was no significant difference in QOL domain scores or minimally clinical important change between the 2 trials. CONCLUSIONS: Prostate and pelvic SABR with a simultaneous DIL boost was feasible. Acute grade ≥2 toxicity, late toxicity, and QOL seemed to be comparable to a cohort that did not receive a focal boost. Further follow-up will be required to assess long-term outcomes, and randomized data are required to confirm these findings.
引用
- Alayed Y, Davidson M, Liu S, et al. Evaluating the Tolerability of a Simultaneous Focal Boost to the Gross Tumor in Prostate SABR: A Toxicity and Quality-of-Life Comparison of Two Prospective Trials. Int J Radiat Oncol Biol Phys. 2020. PMID: 31987962. doi:10.1016/j.ijrobp.2019.12.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。